Adaptimmune Therapeutics plc - American Depositary Shares (ADAP) Covered Calls
You can sell covered calls on Adaptimmune Therapeutics plc - American Depositary Shares to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for ADAP (prices last updated Fri 4:16 PM ET):
| Adaptimmune Therapeutics plc - American Depositary Shares (ADAP) Stock Quote | ||||||
|---|---|---|---|---|---|---|
| Last | Change | Bid | Ask | Volume | P/E | Market Cap |
| 0.65 | +0.03 | 0.65 | 0.65 | 1.1M | - | 0.0 |
| Covered Calls For Adaptimmune Therapeutics plc - American Depositary Shares (ADAP) | ||||||
|---|---|---|---|---|---|---|
| Expiration | Strike | Call Bid | Net Debit | Return If Flat |
Annualized Return If Flat |
|
| Jan 17 | 0.5 | 0.05 | 0.60 | -16.7% | -406.4% | |
| Feb 21 | 0.5 | 0.00 | 0.65 | -23.1% | -168.6% | |
| Subscribers get access to the full covered call chain, and more features. | ||||||
Want to make money with covered calls? Sign Up For A Free Trial
Extended Business Description
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on the provision of cancer immunotherapy products based on its proprietary Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. Its platform enables in identifying cancer targets; finding and genetically engineering T-cell receptors (TCR); and producing TCR therapeutic candidates for administration to patients. It is developing MAGE A-10 peptide that is in Phase I/II clinical trials for the treatment of urothelial, melanoma, and head and neck cancers, as well as non-small cell lung cancer (NSCLC); MAGE-A4 to treat urothelial, melanoma, head and neck, ovarian, NSCLC, esophageal, and gastric cancers; and AFP SPEAR T-cell therapeutic candidate that is in Phase I/II clinical trials for targeting a peptide associated with hepatocellular carcinoma. Adaptimmune Therapeutics plc has a strategic collaboration and licensing agreement with GlaxoSmithKline for the development and commercialization of the NY-ESO SPEAR T-cell program; and strategic alliance with The University of Texas MD Anderson Cancer Center for the development of T-cell therapies for various cancers. The company also has a clinical trial collaboration agreement with Merck & Co., Inc. for the assessment of NY-ESO SPEAR T-cell therapy in combination with anti-programmed death-1 inhibitor in patients with multiple myeloma; and a research, collaboration, and license agreement with Universal Cells, Inc. to gene editing and HLA-engineering technology, as well as a co-development and co-commercialization agreement with Bellicum Pharmaceutical Inc. to evaluate, develop, and commercialize next generation T-cell therapies. Adaptimmune Therapeutics plc was founded in 2014 and is headquartered in Abingdon, the United Kingdom.
| Top 10 Open Interest For Jan 17 Expiration | Top 5 High Yield | |||||
|---|---|---|---|---|---|---|
| 1. | NVDA covered calls | 6. | SPY covered calls | 1. | QSI covered calls | |
| 2. | SLV covered calls | 7. | XLF covered calls | 2. | RIVN covered calls | |
| 3. | AAPL covered calls | 8. | IWM covered calls | 3. | QUBT covered calls | |
| 4. | EEM covered calls | 9. | TSLA covered calls | 4. | QBTS covered calls | |
| 5. | INTC covered calls | 10. | TLT covered calls | 5. | IONQ covered calls | |
Want more examples? ACWX Covered Calls | ADBE Covered Calls
